GlaxoSmithKline and Anacor Pharmaceuticals form alliance to develop systemic antivirals and antibiotics based on boron chemistry
Anacor Pharmaceuticals and GlaxoSmithKline announced that they have entered into a worldwide strategic alliance for the discovery, development and commercialization of novel medicines for viral and bacterial diseases. The collaboration provides GlaxoSmithKline access to Anacor's proprietary boron-based chemistry for use against selected targets.
GlaxoSmithKline will participate in the alliance through its Infectious Diseases Centre of Excellence for Drug Discovery (ID CEDD). Under the terms of the agreement, Anacor will grant GlaxoSmithKline options to select product candidates developed under the collaboration that are directed to up to four discovery targets and with the potential for at least eight product options. Anacor will primarily be responsible for the discovery and development of boron-containing small molecule drug candidates through clinical proof of concept, at which point GlaxoSmithKline will have an exclusive option to license each compound for further development and commercialization on a worldwide basis. Anacor will have the right to further develop and commercialize compounds for which GlaxoSmithKline does not exercise its option. Anacor will receive a $12 million upfront payment and a $10 million equity financing commitment from GlaxoSmithKline. Contingent on achieving certain milestones, Anacor is eligible to receive discovery, development, regulatory and commercial milestones ranging up to $252 million and $331 million for each product candidate. If GlaxoSmithKline exercises its option at the proof of concept stage, Anacor will receive tiered double digit royalties, which are dependent on sales achieved.
Boron has been a relatively underutilized element in pharmaceutical products, in part due to a lack of naturally occurring boron-containing molecules to guide rational drug design. As a consequence of boron's unique properties, boron containing molecules may access different chemical space than traditional anti-infectives, providing opportunities for structural and biological novelty. Anacor's proprietary technological advances in the synthesis of boron-based compounds coupled with its rational drug design expertise, has enabled the company to rapidly create diverse families of boron-based compounds.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Last viewed contents
Nobel Prize in Physics 2016
LAUDA declared World Market Leader
Electrocatalysis under the atomic force microscope - More insights with AFM
Edinburgh Instruments Ltd. - Livingston, United Kingdom
W. Dimer GmbH - Laufenburg, Germany
In chemical reactions, water adds speed without heat
More Electricity from the Sun - Surface modification for more effective textured perovskite/silicon tandem solar cells
Solid or liquid - the particle size matters - Max Planck researchers elucidate how the phase state of aerosol nanoparticles depends on their size
Climate Change makes Arctic Ozone Loss Worse - The expected recovery of the ozone layer may fail to happen anytime soon, if global warming is not slowed down
Applied Biosystems/MDS Sciex is the Top Supplier in the Mass Spectrometer Market
Fighting microplastics for a cleaner future - Dr. Manish Shetty is working to break down microplastics to create usable fuel
